Seeking Alpha

Ilumina ups guidance after Q2 results

  • Ilumina (ILMN +2.5%) Q2 results: Total Revenue: $447.6M (+29.3%), Product Revenue: $390.8M (+24.7%); Cost of Revenue: $147.0M (+19.8%); R&D Expense: $83.0M (+22.7%); SG&A Expense: $114.6M (+29.2%); Operating Income: $100.2M (+67.0%); Net Income: $46.6M (+29.8%); EPS: $0.31 (+19.2%); CF Ops: $178.0M (+100.9%); Quick Assets: $1,103.1M (-5.4%).
  • 2014 Guidance: Revenue growth: 25 - 26%; non-GAAP EPS: $2.26 - 2.28.
Comments (5)
  • LONGTERM RICHARD
    , contributor
    Comments (30) | Send Message
     
    Illumina's Q2 results are a continuation of their long term trend:
    Total Revenue + 29.3%
    Net Income + 29.8%
    2014 Revenue growth ( Guidance ) + 25-26 %
    ILMN has a great track record and a high place in my long term " growth category " holdings;
    I recentlly sold DRQ and added to my ILMN.--No Regrets
    23 Jul, 08:08 PM Reply Like
  • BRZ
    , contributor
    Comments (5) | Send Message
     
    Why would $ILMN drop 3% after great earnings call?
    24 Jul, 11:47 AM Reply Like
  • LONGTERM RICHARD
    , contributor
    Comments (30) | Send Message
     
    To: BRZ -- Good question and I don't have the answer yet. Hopefully it's something basic like
    speculators taking profits on the big run up yesterday. I'm unaware of any downside info and have no reason for concern at this time.
    24 Jul, 03:35 PM Reply Like
  • LONGTERM RICHARD
    , contributor
    Comments (30) | Send Message
     
    To: BRZ-- I think your question is answered by Investors Business Daily, July 25, Page A4--
    in a 2 column article that said ' Biotech stocks in general fell t
    25 Jul, 03:56 PM Reply Like
  • LONGTERM RICHARD
    , contributor
    Comments (30) | Send Message
     
    T0: BRZ-- I Think your question is answered by Investors Business Daily,July 25, Page A4-
    2 column article that said: " Biotech stocks in general fell, especially the big caps Gilead and Illumina--biotech stocks have been volatile in the wake of Janet Yellen's comments last week that biotech valuations were " stretched " based on price to earnings ratios." ---Sorry for the delay in writing this --I had keyboard problems.
    26 Jul, 01:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|